Composition for preventing or treating lung cancer, comprising protosappanin b and osimertinib

WO2026038752A1PCT designated stage Publication Date: 2026-02-19UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2025/011140
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-14
Filing Date
2025-07-28
Publication Date
2026-02-19

AI Technical Summary

Technical Problem

Current treatments for non-small cell lung cancer (NSCLC) are ineffective against resistance to osimertinib, a third-generation EGFR-TKI, and there is a lack of effective therapies for NSCLC resistant to EGFR-TKIs and negative for the EGFR T790M mutation, leading to high recurrence rates and limited survival rates.

Method used

A combination of protosaphanin B, derived from safflower, with osimertinib enhances anticancer effects by increasing sensitivity to EGFR-TKIs in resistant lung cancer, reducing tumor volume, and modulating apoptosis-related proteins.

Benefits of technology

The combined administration of protosaphanin B and osimertinib demonstrates a synergistic effect in reducing tumor volume and increasing drug sensitivity in third-generation EGFR TKI-resistant lung cancer models, including NSCLC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2025011140_19022026_PF_FP_ABST
    Figure KR2025011140_19022026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for treating lung cancer, the composition comprising Protosappanin B and Osimertinib. Co-administration of Protosappanin B and Osimertinib according to the present invention was found to reduce tumor volume in a third-generation EGFR TKI-resistant lung cancer animal model, and was thus found to increase anticancer drug sensitivity in EGFR TKI-resistant lung cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for the treatment of cancer

    WO2023187037A1